drugset / Trial / NCT06685965

A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances

NCT06685965 ↗

Phase 2 Recruiting 24 enrolled Reconnect Labs University of Zurich · collab
RandomizedCrossoverTriple-blindTreatment

Summary

Post-traumatic stress disorder (PTSD) affects many people who have experienced traumatic events. A common issue with PTSD is severe sleep disturbances, such as nightmares. Current treatments often do not provide sufficient relief, especially for sleep problems. This study aims to determine whether dexmedetomidine - a medication already used in intensive care - can improve sleep quality in PTSD patients.

Timeline

Start
2025-09-10
Primary completion
2026-08-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject RE03 Unknown — Other